The Plant-Derived Solution Your Patients Have Been Waiting For. request sample


Committed to Scientific Research and Discovery

With more than 20 years of safe, effective use in Europe (backed by decades of postmarketing surveillance data), ERr 731® has been clinically demonstrated, through extensive research, including RCTs, to safely and effectively reduce menopausal symptoms.4 ERr 731® is a therapy designed to alleviate the uncomfortable physical symptoms of menopause, including hot flashes.*1-3

ALL women will experience menopause. About 75% of women experiencing menopause will have hot flashes.5
12-week confirmatory RCT
  • 112 perimenopausal women were included in a 12-week randomized clinical trial. (Kaszkin-Bettag, et al. Altern Ther Health Med. 2009)

  • At 12 weeks, ERr 731® group showed a significant reduction in the number of hot flashes compared to placebo, from a median of 12 to 2—an 83% reduction.* (Figure 1)

  • The Hot-Flash-Weekly-Weighted-Score (HFWWS) was significantly decreased in ERr 731® group (p<0.0001) but not the placebo group.*

6-month observational study (OS)
  • 252 peri- and postmenopausal women from 70 gynecological practices were included in a 6-month observational study (Kaszkin-Bettag M, et al. Altern Ther Health Med. 2008)

  • Subjects showed a significant decrease in Menopause Rating Scale (MRS) total score from a mean of 14.5 points at baseline to 6.5 at 6 months (p<0.0001); all 11 individual symptom scores were improved over baseline.* (Figure 2)

  • 90% of women rated the tolerability of ERr 731® "very good" or "good," and there were no ERr 731®-related AEs

View References
By 2025, the number of postmenopausal women worldwide is expected to rise to 1.1 billion.7

Ready to get your patients started?

Request Sample